Please wait ...

John P Breinholt III, MD, FACC, FSCAI, FAAP

Phoenix Children's Hospital


John Breinholt, MD, FACC, FSCAI, FAAP is currently the Chief of Pediatric Cardiology and Director of Cardiac Catheterization Laboratories at Phoenix Children’s Hospital and Professor of Child Health at the University of Arizona College of Medicine – Phoenix. He graduated from the University of Utah School of Medicine in 2000 and completed post graduate training in Pediatrics, Pediatric Cardiology and advanced training in Pediatric Interventional Cardiology at Baylor College of Medicine and Texas Children’s Hospital in Houston, TX. Dr. Breinholt completed his training in 2008 and joined the faculty of Indiana University School of Medicine and Riley Hospital for Children in Indianapolis, IN. There he was the program director of the Pediatric Cardiology Fellowship Program and had established an animal lab creating models of congenital heart disease. Dr. Breinholt was appointed Chief of Pediatric Cardiology at Children’s Memorial Hermann Hospital in 2014. He was also appointed Division Director of Pediatric Cardiology at UTHealth in 2014. Shortly after joining UTHealth, he also directed the Pediatric Cardiology fellowship program. Dr.Breinholt has worked for many years in medical school and residency training, including developing curriculum for rotating residents. He has directed 2 cardiology fellowship programs and has a strong interest in the professional development of trainees and faculty. He also enjoys participating in humanitarian medical missions and has participated in more than 20 around the world. Dr. Breinholt is the director of the pediatric cardiac catheterization laboratories. He has worked to bring the latest technologies to children with congenital heart disease and has a recent focus on the delivery of PDA occlusion devices in premature babies. He makes efforts to offer minimally invasive closure of ventricular septal defects.


Dr. Breinholt's lecture includes discussion of "off-label" substances/products not approved by the FDA for use under discussion or substances/products that are being investigated for such use.